Related Experiment Video
Updated: Aug 20, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Cystic fibrosis in adults: current and future management strategies
Brian M Morrissey1, Bettina C Schock, Gregory P Marelich
1Adult Cystic Fibrosis Clinic and University of California Davis School of Medicine, Sacramento, CA, USA. bmmorrissey@ucdavis.edu
Insights
Cystic Fibrosis (CF) affects over 30,000 Americans, remaining life-limiting despite advances. This review covers CF respiratory issues, management, and future therapies for improved patient outcomes.
Area of Science:
- Pulmonary Medicine
- Genetics
- Pediatrics
Background:
- Cystic Fibrosis (CF) impacts over 30,000 individuals in the US.
- Despite advancements, CF remains a significant life-limiting illness.
- Early recognition is increasing due to newborn screening, genetic testing, and awareness.
Purpose of the Study:
- To review the pathophysiology, diagnosis, and management of respiratory manifestations in CF.
- To summarize current and future therapeutic strategies for CF patients.
Main Methods:
- Literature review of CF pathophysiology.
- Analysis of diagnostic approaches for CF respiratory disease.
- Summary of current and emerging CF treatments.
Main Results:
- Severe lung disease is the primary life-limiting pathology in CF.
- Medical management has improved life expectancy for CF patients.
- Newborn screening and genetic testing enhance early diagnosis.
Conclusions:
- Respiratory complications are central to CF's life-limiting nature.
- Ongoing research and improved therapies offer hope for better CF management.
- Future therapies aim to further improve outcomes for individuals with CF.
Abstract:
Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.
More Related Videos
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Pancreatitis II: Collaborative Care
Assessment:

